CalciMedica, Inc. Common Stock (CALC)vsRevolution Medicines Inc (RVMD)
CALC
CalciMedica, Inc. Common Stock
$1.60
-3.03%
HEALTHCARE · Cap: $11.88M
RVMD
Revolution Medicines Inc
$206.64
+0.36%
HEALTHCARE · Cap: $41.32B
Smart Verdict
WallStSmart Research — data-driven comparison
RVMD leads profitability with a 0.0% profit margin vs 0.0%. CALC earns a higher WallStSmart Score of 25/100 (F).
CALC
Avoid25
out of 100
Grade: F
RVMD
Avoid24
out of 100
Grade: F
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Conservative balance sheet, low leverage
Areas to Watch
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Trading at 17.0x book value
0.0% earnings growth
0.0% margin — thin
Operating margin of 0.0%
Comparative Analysis Report
WallStSmart ResearchBull Case : CALC
The strongest argument for CALC centers on Price/Book.
Bull Case : RVMD
The strongest argument for RVMD centers on Debt/Equity.
Bear Case : CALC
The primary concerns for CALC are Revenue Growth, EPS Growth, Market Cap.
Bear Case : RVMD
The primary concerns for RVMD are Price/Book, EPS Growth, Profit Margin.
Key Dynamics to Monitor
RVMD carries more volatility with a beta of 1.41 — expect wider price swings.
CALC is growing revenue faster at 0.0% — sustainability is the question.
CALC generates stronger free cash flow (-5M), providing more financial flexibility.
Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.
Bottom Line
CALC scores higher overall (25/100 vs 24/100). Both earn "Avoid" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
CalciMedica, Inc. Common Stock
HEALTHCARE · BIOTECHNOLOGY · USA
CalciMedica, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing innovative therapies that target calcium-dependent pathways to address both acute and chronic health challenges. The company’s lead candidate, CM4620, aims to alleviate severe muscle cramps associated with sickle cell disease, underscoring its focus on meeting critical unmet medical needs. With a robust proprietary technology platform and an expanding pipeline of novel calcium modulators, CalciMedica is well-positioned for significant growth. Backed by an experienced management team and key strategic partnerships, the company presents a compelling investment opportunity within the biopharmaceutical sector.
Revolution Medicines Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Revolution Medicines, Inc., a precision clinical-stage oncology company, is focused on developing therapies to inhibit borderline targets in RAS-addicted cancers. The company is headquartered in Redwood City, California.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?